Primmune Therapeutics to Present PRTX007 Phase 1 Pharmacology and Phase 2 INFLECTION-003 Study Design at the SITC 41st Annual Meeting

Nov 3, 2026 | Press Releases

SAN DIEGO, November 3, 2026 – Primmune Therapeutics, a clinical-stage biotech company harnessing the power of the innate and adaptive immune systems, today announced that two abstracts on polvitolimod HCl (also known as PRTX007), a novel orally administered,...

Primmune Therapeutics Announces Enrollment Milestone in Phase 2 INFLECTION–003 Study of Polvitolimod HCl in Neoadjuvant Melanoma

Sep 24, 2026 | Press Releases

SAN DIEGO, Sept. 24, 2026 — Primmune Therapeutics, a biotech company harnessing the power of the innate and adaptive immune system, today announced the enrollment of the second patient in its Phase 2 INFLECTION-003 clinical study triggering the release of the...

Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board

Feb 5, 2026 | Press Releases

Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth SAN DIEGO, February 5, 2026 – Primmune Therapeutics, Inc., a biotech company harnessing the power of the innate immune system, today announced the...

Primmune Therapeutics Announces Additional Close of Series B Financing

Jan 26, 2026 | Press Releases

SAN DIEGO, January 26, 2026 – Today, Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total of $8.6 million with participation from Bioqube Ventures, Oberland...

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

Mar 20, 2024 | Press Releases

– PRTX007 program to support DTRA’s efforts to establish biological defense solution against Lassa fever and other hemorrhagic viruses – SAN DIEGO, March 20, 2024 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, today...

Primmune Therapeutics Presents Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Nov 10, 2023 | Press Releases

— PRTX007 demonstrated a favorable safety profile for all analyzed cohorts with no serious adverse events (SAEs) observed — — Well-controlled activation of innate and adaptive immune response observed without increases in proinflammatory factors — — Data support...